Skip to content
Review

Abstract 13508: Elevated Plasma miR-92a as a Potential Risk Stratification Biomarker in Patients with Chronic Coronary Syndrome: A 2-Year Follow-Up Study

Nov 2026 · Circulation · 0 citations

Abstract

Introduction: MicroRNAs are emerging biomarkers involved in the regulation of endothelial function andatherosclerotic plaque progression. MicroRNA-92a (miR-92a) downregulates Kruppel-likefactor 2 (KLF2), a key mediator of endothelial homeostasis and atheroprotection.Although elevated miR-92a expression has been linked to atherosclerotic disease, itsprognostic significance in Chronic Coronary Syndrome (CCS) remains unclear. Thepresent study evaluated the prognostic and risk-stratification value of baseline plasmamiR-92a expression in patients with angiographically confirmed CCS. Methods: Fifty-six patients with angiographically confirmed coronary artery disease and no historyof myocardial infarction were prospectively enrolled. Baseline plasma expression levels ofmiR-92a, miR-10b, miR-126, miR-98 and miR-29b were measured using RT-qPCR withspike-in normalization. Patients were followed up with after 24 months. Adversecardiovascular events were defined as death due to cardiovascular reason, myocardialinfarction, stroke, or unplanned cardiovascular hospitalization. Follow-up data wereobtained through structured telephone interviews and review of local hospital database(CliniNet). Receiver operating characteristic (ROC) analysis was performed to determinethe optimal miR-92a threshold for event discrimination. Results: Adverse cardiovascular events occurred in 15 of 56 patients (26.8%) during the 24-monthfollow-up period. Patients experiencing events demonstrated significantly higher baselinemiR-92a expression compared with event-free patients (102.96 [67.67-150.75] vs. 67.04[40.67-87.40]; p=0.017). No significant associations were observed for other investigatedmicroRNAs (miR-10b, miR-126, miR-98, or miR-29b). ROC analysis identified a miR-92athreshold of 91.92 for prediction of adverse cardiovascular events (AUC=0.706, sensitivity66.7%, specificity 75.0%). To assess clinical risk stratification, biomarker data werecombined with left ventricular ejection fraction (LVEF). The presence of either elevatedmiR-92a (>91.92) or reduced LVEF (<50%) was associated with substantially increasedodds of adverse cardiovascular events during follow-up (OR=14.0, 95% CI 2.75-71.28,p=0.0005). Conclusions: Elevated baseline miR-92a expression is associated with adverse cardiovascularoutcomes in patients with CCS. A miR-92a threshold of 91.92 demonstrated moderatediscriminatory performance, while the combination of elevated miR-92a or reduced LVEFidentified a subgroup at markedly increased risk of adverse cardiovascular events. Thesefindings suggest that circulating miR-92a may provide incremental prognostic informationbeyond established clinical parameters and warrant further investigation as a biomarkerfor cardiovascular risk stratification in chronic coronary syndrome.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.